SWAMY, Ganesha, Julie BIENERTOVÁ VAŠKŮ, Petr BIENERT, Ota HLINOMAZ and Anna VAŠKŮ. Atrial Natriuretic Peptide: IS ANP associated with restenosis after Coronary Artery Disease? In New Frontiers in Basic Cardiovascular Research. Hungary: INSERM, France, 2006, p. 82-82.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Atrial Natriuretic Peptide: IS ANP associated with restenosis after Coronary Artery Disease?
Name in Czech Je variabilita v genu pro atriální natriuretický peptid asociována s výskytem restenózy po PCI?
Authors SWAMY, Ganesha (826 United Kingdom of Great Britain and Northern Ireland), Julie BIENERTOVÁ VAŠKŮ (203 Czech Republic, guarantor), Petr BIENERT (203 Czech Republic), Ota HLINOMAZ (203 Czech Republic) and Anna VAŠKŮ (203 Czech Republic).
Edition Hungary, New Frontiers in Basic Cardiovascular Research, p. 82-82, 1 pp. 2006.
Publisher INSERM, France
Other information
Original language English
Type of outcome Proceedings paper
Field of Study Genetics and molecular biology
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
RIV identification code RIV/00216224:14110/06:00017441
Organization unit Faculty of Medicine
Keywords in English Atrial natriuretic peptide; restenosis; PCI
Tags Atrial natriuretic peptide, PCI, restenosis
Changed by Changed by: prof. MUDr. Julie Dobrovolná, Ph.D., učo 4805. Changed: 2/11/2006 15:10.
Abstract
Background: ANP has shown over recent studies to play an increasingly pivotal role in the regulation of coronary blood flow and atherosclerosis. The gene polymorphism of interest, transition T2238C (ScaI) in the ANP precursor gene, leads to the abolishment of the regular stop codon and instead translation of an additional two arginines. The purpose of the study is to identify the possible influence of ANP ScaI polymorphism on restenotic phenotypes in coronary artery disease (CAD) patients. Method: This study was performed on 96 consecutive caucasians (24 women and 72 men) with clinically significant coronary artery disease confirmed by means of quantitave coronary angiography with minimum one coronary artery with more than 50% lumen stenosis, and all with bare metal stenting in coronary arteries < 3mm. Results: No differences were found in relation to patients with or without restenosis and the genotype distributions as well as allelic frequencies of examined ANP ScaI polymorphism (p = 0.28). However, there is a borderline significant association of ANP genotype distribution with CAD risk factors, such as hypertension and hyperlipidemia (p = 0.05). According to our findings, the allelic frequencies of the ANP ScaI polymorphism in the Czech CAD population do statistically significantly differ from those described in Polish CAD patients (p = 0.01). Conclusion: The ANP ScaI gene polymorphism, based on our data, is not a genetic marker for restenosis after stenting in CAD patients, but the study does suggest that ANP genotypes, specifically A2A2 variants, may be conducive to hypertension. This may be explained by impaired natriuresis in the kidney, perhaps due to reduced affinity or impaired binding of ANP to its receptor, thus leading to sodium retention and increased extracellular volume. Continued research into ANP and its pathophysiological role we believe is imperative to further elucidate how ANP is associated to hypertension.
Abstract (in Czech)
Polymorfismus ScaI v genu pro atriální natriuretický peptid se nezdá být velkým faktorem pro rozvoj restenózy po PCI.
Links
MSM 141100002, plan (intention)Name: Molekulární patofyziologie multigenních chorob
Investor: Ministry of Education, Youth and Sports of the CR, Molecular pathophysiology of multigene diseases
PrintDisplayed: 25/4/2024 06:39